date,title,source
Oct-17-18,EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq,Zacks
Oct-18-18,EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ to be Presented at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting,GlobeNewswire
Oct-29-18,EyePoint Pharmaceuticals Presents Positive YUTIQ 24-month Follow-up Data at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting,GlobeNewswire
Oct-30-18,EyePoint Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results Release Date and Conference Call Information,GlobeNewswire
Oct-30-18,"EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors",GlobeNewswire
Nov-05-18,EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region,GlobeNewswire
Nov-06-18,EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference,GlobeNewswire
Nov-06-18,"EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates",Zacks
Nov-06-18,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",Benzinga
Nov-06-18,EyePoint Pharmaceuticals: Fiscal 1Q Earnings Snapshot,Associated Press
Nov-06-18,EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments,GlobeNewswire
Nov-12-18,EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU by the Center for Medicare and Medicaid Services (CMS),GlobeNewswire
Nov-27-18,"EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary",GlobeNewswire
Nov-29-18,Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options,Zacks
Dec-17-18,EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index,GlobeNewswire
